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ABSTRACT 
 
The gene mutation is one of the background underlie the pathogenesis of pulmonary artery 
hypertension (PAH). Several genes have been recognized to be responsible for the 
development of PAH. The mutation in transforming growth factor-β (TGF-β) pathway is 
considered to be major genotype background in heritable PAH. The genetic mutation in bone 
morphogenetic protein receptor-2 (BMPR2), activin receptor-like kinase 1 (ALK-1) and endoglin 
(ENG) are known to cause heritable PAH. In congenital heart disease–associated PAH (CHD-
APAH), their mutation are also presence.  
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INTISARI 
 
Mutasi genetik merupakan salah satu kondisi yang mendasari patogenesis hipertensi arteri paru 
(HAP). Beberapa gene telah dikenal bertanggungjawab terhadap terjadinya HAP. Mutasi pada 
gen jalur transforming growth factor-β (TGF-β) diduga merupakan melatarbelakangi HAP yang 
diwariskan. Mutasi gen pada bone morphogenetic protein receptor-2 (BMPR2), activin receptor-
like kinase 1 (ALK-1) dan endoglin (ENG) diketahui menyebabkan HAP yang diwariskan. Pada 
HAP yang terkait penyakit jantung kongenital, mutasi pada gen tersebut juga terjadi.  
 
INTRODUCTION 
Pulmonary artery hypertension 
(PAH) is a disease of pulmonary artery 
obstruction, due to complex plexyform 
lesions in the distal artery, with subsequent 
elevation in pulmonary vascular resistance.1 
Right ventricular failure will develop in the 
eventual process of PAH.1 The PAH is 
characterized by a persistent increase in 
mean pulmonary artery pressure (≥ 25 mm 
Hg at rest), a normal value of pulmonary 
capillary wedge pressure (≤ 15 mmHg) and 
an increased level of pulmonary vascular 
resistance (> 3 Wood units).2 Clinically, the 
PAH can be divided into idiopathic PAH, 
heritable PAH, or associated with other 
conditions (APAH).  
Several diseases can be associated 
with PAH, such as such as drug-induced, 
toxin exposures, connective tissue 
diseases, human immunodeficiency virus 
infection, portal hypertension, congenital 
heart disease and schistosomiasis.2 
Heritable PAH is recognized by the 
presence of genetic mutation.
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The genetic mutation in bone 
morphogenetic protein receptor-2 (BMPR2) 
gene has been reported in about 75% of 
heritable PAH and nearly 25% of sporadic 
PAH.3 Other mutations of gene encoding 
activin receptor-like kinase 1 (ALK-1) and 
endoglin (ENG) have been recognized in 
PAH with a history of hereditary 
haemorrhagic telangiectasia.3 
Pathophysiology of PAH is 
multifactorials and can be attributed to 
various pathologies. One of the important 
aspects of pathophysiology of PAH is the 
role of genetic factors such as mutations in 
BMPR2, ALK1 and ENG genes. The 
BMPR2, ALK1 and ENG gene mutations 
have been determined to have a high level 
of evidence as a causal role in PAH.4 The 
congenital heart disease–associated PAH 
(CHD-APAH) most commonly occurs with 
septal defect and systemic-to-pulmonary 
shunt lesions. It accounts for around 10% of 
all patients with PAH.5 Pulmonary 
hypertension in this condition is due to  
increasing blood flow in pulmonary vascular 
systems and subsequent endothelial 
damage and pulmonary vascular 
remodeling. The pulmonary vascular lesions 
in CHD-APAH are similar with lesions in 
idiopathic PAH and heritable PAH.5 In CHD-
APAH), the role of genetics mutations has 
been reported, however the result until 
currently cannot be completely concluded 
yet. 
 
THE BMPR2 GENE MUTATION IN 
CHD-APAH 
Mutation in BMPR2 genes has been 
recognized in 70-80% of familial PAH and 
10-20% of idiopathic PAH. BMPR2 is gene 
that encode BMPR2 protein, a member of 
the transforming growth factor-β (TGF-β) 
receptor superfamily.4 The BMPR2 is an 
active serine-threonine kinase receptor 
which is expressed constitutively in the 
lung.1 Ligation of BMPR2 by its ligands 
(BMP2, BMP4, BMP6, BMP7, BMP9 and 
BMP10), triggers BMPR2 phosphorylation 
and Smad protein-signaling activation.1 
The BMPR2 mutations in PAH result 
in derangement of Smad signaling 
pathways, which increases the tendency of 
endothelial and artery smooth muscle cells 
to proliferate and reduce their apoptotic 
capacity.4 BMPR2 receptor-activated Smads 
forms a complex with Smad4 (canonical 
pathway) and translocatesinto the nucleus, 
where it regulates gene transcription.1 Other 
Smad4-independent pathways are related 
to Smad8 pathway, in which mutation of 
SMAD9 gene (gene encodes Smad8) leads 
to significant loss of function in microRNA 
maturation and is implicated in PAH 
pathogenesis.4 SMAD9 mutation 
demonstrates a cellular hyperproliferative 
state, blunted BMP signaling, and 
dysregulated Smad-mediated microRNA 
activity.6 Drake et al. reported the case of 
dyregulated SMAD9 pathway in CHD-
APAH.6 The majority of the patients with 
heritable PAH have mutations in BMPR2 
which causes increased cellular 
proliferation.7 Furthermore, BMPR2 mutation 
patients with PAH have more severe clinical 
condition and low response to acute 
vasodilator testing.7 
The prevalence of PAH-associated 
mutations in the CHD-APAH population 
indicate that up to 10% have a 
germline BMPR2 mutation.8 Robert et al. 
reported six missense BMPR2 mutations in 
exons 2 and 3 (an extracellular domain of 
BMPR2), exon 5 (kinase domain for 
phosporylation) and exon 11 (cytoplasmic 
tail with unknown function), which 
associated with  altered protein sequence at 
evolutionary conserved amino acids and 
deranged BMPR2 function.8 Patients with 
BMPR2 mutations were identified as having 
atrioventricular septal defects (AVSD) and 
multiple defects (ASD+PDA, ASD+PDA and 
PAPVD, and AP window+VSD).8 A study in 
11 children with CHD-APAH (10 ASD and 1 
VSD) indicated 1 subject (female, VSD) with 
BMPR2 mutation (deletion in exon 1).9 
Study in Chinese CHD-APAH population 
indicated mutation rate of 7.5% in BMPR2 
gene among CHD-APAH, whereas in CHD
Hartopo et al., 2019                                                          ACI (Acta Cardiologia Indonesiana) (Vol.5 No.2): 145-149 
147 
 
with no PAH the mutation rate of BMPR2 is 
much lower (1.2 %).10 Females have 
increased BMPR2 mutation rate and the 
dominant mutation type is missense 
mutation.10 The type of defects were not 
associated with BMPR2 mutation.10 
BMPR2 is highly expressed on the 
pulmonary vascular endothelial cells.4 It 
forms a complex with the type I receptors, 
ALK1.4 The complex of ALK1/BMPR2 
receptor signaling pathway requires the 
utilization of ENG as a co-receptor.4 This 
membrane bound receptor complex 
regulates various cellular processes 
including cell differentiation, proliferation, 
and apoptosis in embryonic and mature 
cells.4 Similar with BMPR2 expression, the 
ALK1 and ENG are also abundantly 
expressed in the pulmonary endothelial 
cells.4,5 Figure 1 shows the diagram  of 
BMPR2/ALK1/ENG complex receptors in 
endothelial cells. The mutation of ALK1 and 
ENG also deranges the BMPR2 
downstream signaling and is implicated in 
the presence of PVD in CHD-APAH.  
 
THE ALK1 GENE MUTATION IN 
CHD-APAH 
Mutation in ALK1, which is also a 
member of the TGF-β receptor superfamily, 
is currently reported in PAH patients, 
although the mutation rate is not as high as 
BMPR2 gene mutation.11 In a European 
cohort of adult-onset PAH, the mutation rate 
of ALK1 gene was 0.9%.4 However this 
collaborative research did not include CHD-
APAH. The ALK1 is located on 
chromosome 12q13 and plays a role in 
various tissues such as cell proliferation and 
differentiation, cell migration, cell survival 
and angiogenesis.4 Its missense mutations 
are located in the serine-threonine kinase 
domain, which is responsible for PAH 
development in patients with hereditary 
hemorrhagic telangiectasia (HHT) as well as 
familial and idiopathic PAH.12 
The HHT and heritable PAH 
represent inherited diseases caused by 
mutation of the TGF-β  receptor-mediated 
signalling, particularly involving ALK1, in the 
vasculatures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The diagram of BMPR2/ALK1/ENG complex receptor in surface membrane of endothelial  
cells which exhibit its role on endothelial cell differentiation, proliferation,  and apoptosis upon ligation by 
BMPs. 
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The TGF-β signaling in endothelial 
cells modulates vascular remodeling, 
therefore mutation in ALK-1 gene may 
induce derangement of remodeling of the 
vascular bed.13 A mutation analysis in 18 
children with PAH (16 idiopathic PAH and 2 
CHD-APAH), detected a missence mutation 
in idiopatic PAH subject but not in CHD-
APAH (BMPR2 mutation instead).14 Another 
study involved 11 children with CHD-APAH 
(10 ASD and 1 VSD) and performed PCR 
amplification of the entire coding regions 
and the exon/intron of the ALK1 gene did 
not find ALK1 mutation.9 
 
THE ENG GENE MUTATION IN 
CHD-APAH 
 Endoglin is a homodimeric 
glycoprotein ubiquitously located in the 
vascular endothelial cells of human body.4 It 
is an integral membrane glycoprotein in the 
celular membranes.4 The ENG gene 
encodes a type I integral membrane 
glycoprotein receptor.4 It belongs to the 
TGF-β signaling superfamily.4 This receptor 
is expressed on proliferating vascular 
endothelial cells and other cell types 
associated with cardiovascular system, in 
which indicate its important of endothelial 
and vascular function. It promotes cell 
differentiation, proliferation, angiogenesis, 
inflammation, and also induce wound 
healings.15 The ENG gene is located on 
chromosome 9q33-34 and the encoded 
protein demonstrates an extracellular 
domain, hydrophobic transmembrane 
domain and a cytosolic domain.15 
 Similar with the mutation on ALK1 
gene, the mutation on ENG gene is 
associated with HHT, in which the mutation 
involved are missense, splicing mutations, 
and novel protein-truncating mutations.13 In 
a European cohort of adult-onset PAH, the 
mutation rate of ALK1 gene was 0.6%.4 
Unfortunately, this collaborative research 
did not include CHD-APAH. The study by 
Harrison et al. in 18 children with PAH, 
found no ENG mutation in CHD-APAH 
patients (only two subjects in this study), but 
only found one branch-site ENG mutation in 
a subject with HHT and IPAH.14 The study 
by Pfarr et al. described a small number of 
pathogenic mutations in patients with CHD-
APAH.9 In 11 children with CHD-APAH 
without history of HHT, 1 patient with 
secundum ASD had mutation in the ENG 
gene (missense mutation in exon 12).9 
 
CONCLUSION 
 In CHD-APAH patients, mutation in 
the TGF-β pathway genes involving 
BMPR2/ALK1/ENG complex receptors is 
needed to be explored. Unlike idiopathic 
PAH and heritable PAH, the genetic 
mutation in CHD-APAH is quite rare and its 
clinical implication need further 
corroboration.  
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